The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial
No positive or adverse effect of infliximab or vedolizumab vs. no biologic agents was shown on presumed hepatic steatosis in patients with IBD, who have not been previously exposed to biologic agents. Although no effect of both biologic agent on LS, a slight but significant increase in FIB-4 and NAFLD fibrosis score warrants further studying.
Authors
- Georgios Agrotis (ORCID: https://orcid.org/0000-0002-3752-1315)
- Styliani Sarrou (ORCID: https://orcid.org/0000-0001-8134-9228)
- Ilias D. Vachliotis (ORCID: https://orcid.org/0000-0001-8550-8652)
- George Ν. Dalekos (ORCID: https://orcid.org/0000-0001-7075-8464)
- Marianna Vlychou (ORCID: https://orcid.org/0000-0002-8104-9847)
- Spyros Potamianos
- Stergios A. Pοlyzos (ORCID: https://orcid.org/0000-0001-9232-4042)
- Andreas Kapsoritakis
- Jannis Kountouras (ORCID: https://orcid.org/0000-0001-6459-5136)
- Ioanna-Konstantina Sgantzou (ORCID: https://orcid.org/0000-0002-0612-2880)
- Apostolis Papaefthymiou (ORCID: https://orcid.org/0000-0002-3563-4973)
- Konstantinos Pateras (ORCID: https://orcid.org/0000-0002-6005-9798)
- Matthaios Speletas (ORCID: https://orcid.org/0000-0003-1287-7734)
- Antonis Goulas (ORCID: https://orcid.org/0000-0002-8844-5631)
- Georgios Perifanos
Institutions
- University of Thessaly (GR)
- Aristotle University of Thessaloniki (GR)
- University Hospital of Larissa (GR)
- 424 General Military Hospital (GR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3390/ph17111432
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.55